Search results | stem cell

Reports

Regenerative Medicine Partnering Terms and Agreements

The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Stem cells

Stem cells are cells found in all multicellular organisms, that can divide and differentiate into diverse specialized…

Bio news: China a potential hub for stem cell research, RBCC’s partnering initiative

In bio news is  Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow Biosciences, which is on a hunt to find potential partners for research collaboration on stem cells in China

Proteonomix examines licensing of diabetes stem cell technology

Proteonomix has that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”).

Shire in the hunt for promising new stem cell tech

The UK’s Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers

Cephalon license Mesenchymal precursor stem cell therapeutics for $2 billion

Cephalon, the largest biotechnology company in the regenerative medicine sector, have licensed Mesenchymal Precursor Stem Cell (MPC) therapeutics from Mesoblast for over $2 billion.

Biotech IPO: Stemline makes first IPO debut of 2013

Biotech IPO: Stemline Therapeutics, an emerging biotech company, successfully completed its biotech IPO yesterday with shares rising 18% on opening

Stemade looking to raise $10 million private equity investment

Report from Financial Chronicle. Stem cell bank Stemade, which is into storing stem cells extracted from the tooth, is looking at foraying into the overseas markets like Singapore, West Asia and Australia in the coming two years. The company also wants to raise around $8 million to $10 million from Private equity funds to drive more »

Dealmakers weekly review – February 13 2012 – Eli Lilly, Roche, UCB, Janssen, Sistemix, TiGenics, Becton Dickinson, SDIX, Aldagen, Carefusion

The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value

Westphal’s Verastem plans $45 million IPO next week

From Boston Business Journal.  Verastem, a one-year old startup focused on developing drugs that target cancer stem cells, plans to set pricing for its IPO during the week of Jan. 23, the IPO research firm Renaissance Capital reported, Friday.

Regenerative Medicine deal trends article

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Events

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Deals

Athersys and Chugai in Multistem cell therapy pact

Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan

Asset purchase agreement for stem cell reagent and services business unit

Stemgent has completed the sale of its stem cell reagents and services business to ReproCELL in a cash transaction for approximately $8.5 million.

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Stem Cell Therapeutics raises $33 million in private financing

Stem Cell Therapeutics has raised gross proceeds of $33 million through a private placement financing.

OncoMed pharma partners with Celgene in anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals and Celgene, big biotech company, pharma partners to jointly develop and commercialize up to six anti-cancer stem cell product candidates from OncoMed’s biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4)

Geron hires Stifel to sell stem cell assets, CEO says

Written by Ryan Flinn for Bloomberg. Geron Corp. hired Stifel Nicolaus & Co. to sell its embryonic stem cell therapy, the first approved in the U.S., as the company changes its focus to cancer drugs, Chief Executive Officer John Scarlett said.

Proteonomix examines licensing of diabetes stem cell technology

Proteonomix has that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”).

Shire in the hunt for promising new stem cell tech

The UK’s Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers

Opexa Therapeuticss stem cell technology acquired by Novartis

Novartis will acquire the stem cell technology from Opexa and Novartis will have full responsibility for funding and carrying out all research, development and commercialization activities. Opexa will receive an upfront cash payment of $3 million, plus an additional $1 million as a technology transfer fee to be paid over the course of a six more »

StemCells in equity purchase financing for $30.6 million

StemCells has entered into an equity purchase financing agreement with Lincoln Park Capital Fund under which the Company has the right to sell up to $30.0 million of common stock to Lincoln Park.